These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 9393862

  • 1. Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.
    Wiesmann C, Fuh G, Christinger HW, Eigenbrot C, Wells JA, de Vos AM.
    Cell; 1997 Nov 28; 91(5):695-704. PubMed ID: 9393862
    [Abstract] [Full Text] [Related]

  • 2. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states.
    Starovasnik MA, Christinger HW, Wiesmann C, Champe MA, de Vos AM, Skelton NJ.
    J Mol Biol; 1999 Oct 29; 293(3):531-44. PubMed ID: 10543948
    [Abstract] [Full Text] [Related]

  • 3. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
    Pan B, Li B, Russell SJ, Tom JY, Cochran AG, Fairbrother WJ.
    J Mol Biol; 2002 Feb 22; 316(3):769-87. PubMed ID: 11866530
    [Abstract] [Full Text] [Related]

  • 4. Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability.
    Davis-Smyth T, Presta LG, Ferrara N.
    J Biol Chem; 1998 Feb 06; 273(6):3216-22. PubMed ID: 9452434
    [Abstract] [Full Text] [Related]

  • 5. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.
    Keyt BA, Nguyen HV, Berleau LT, Duarte CM, Park J, Chen H, Ferrara N.
    J Biol Chem; 1996 Mar 08; 271(10):5638-46. PubMed ID: 8621427
    [Abstract] [Full Text] [Related]

  • 6. Characterization of the VEGF binding site on the Flt-1 receptor.
    Herley MT, Yu Y, Whitney RG, Sato JD.
    Biochem Biophys Res Commun; 1999 Sep 07; 262(3):731-8. PubMed ID: 10471394
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase).
    Tanaka K, Yamaguchi S, Sawano A, Shibuya M.
    Jpn J Cancer Res; 1997 Sep 07; 88(9):867-76. PubMed ID: 9369935
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding.
    Yu Y, Hulmes JD, Herley MT, Whitney RG, Crabb JW, Sato JD.
    Biochem J; 2001 Sep 01; 358(Pt 2):465-72. PubMed ID: 11513746
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF.
    Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M.
    Oncogene; 1995 Jan 05; 10(1):135-47. PubMed ID: 7824266
    [Abstract] [Full Text] [Related]

  • 14. Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells.
    Frank S, Stallmeyer B, Kämpfer H, Schaffner C, Pfeilschifter J.
    Biochem J; 1999 Mar 01; 338 ( Pt 2)(Pt 2):367-74. PubMed ID: 10024512
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z.
    Cancer Res; 2001 Oct 01; 61(19):7002-8. PubMed ID: 11585724
    [Abstract] [Full Text] [Related]

  • 17. Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis.
    Valter MM, Hügel A, Huang HJ, Cavenee WK, Wiestler OD, Pietsch T, Wernert N.
    Cancer Res; 1999 Nov 01; 59(21):5608-14. PubMed ID: 10554042
    [Abstract] [Full Text] [Related]

  • 18. Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes.
    Takagi H, King GL, Aiello LP.
    Diabetes; 1996 Aug 01; 45(8):1016-23. PubMed ID: 8690146
    [Abstract] [Full Text] [Related]

  • 19. Interactions of FLT-1 and KDR with phospholipase C gamma: identification of the phosphotyrosine binding sites.
    Cunningham SA, Arrate MP, Brock TA, Waxham MN.
    Biochem Biophys Res Commun; 1997 Nov 26; 240(3):635-9. PubMed ID: 9398617
    [Abstract] [Full Text] [Related]

  • 20. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.
    Sawano A, Takahashi T, Yamaguchi S, Aonuma M, Shibuya M.
    Cell Growth Differ; 1996 Feb 26; 7(2):213-21. PubMed ID: 8822205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.